HTHiroyuki Tsuji

Hiroyuki Tsuji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroyuki Tsuji has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PRDX4 Potentially Predicts the Postoperative Outcome in Advanced Papillary Thyroid Carcinoma

    by Yuki Takaoka, Xin Guo, Akihiro Shioya, Jia Han, Yuzo Shimode, Yoshiaki Kobayasi, Morimasa Kitamura, Hiroyuki Tsuji, Sohsuke Yamada

    Background: Peroxiredoxin 4 (PRDX4), a secreted antioxidant enzyme, can protect against hepatocellular carcinoma and lung adenocarcinoma, but its role in papillary thyroid carcinoma (PTC) is still unclear. In this study, we investigated the association of the PRDX4 expression with the prognosis of patients with advanced PTC. Methods: We conducted a retrospective case-control study at Kanazawa Medical University Hospital. We selected PTC patients over 55 years of age who received surgery from 2006 to 2014. The PRDX4 expression was immunohistochemically analyzed in paraffin-embedded tumor specimens of 70 patients with stages Ⅱ–Ⅳ advanced PTC. We also investigated the key roles of PRDX4 in a human PTC cell line (K-1) in vitro. Result: The weak expression of PRDX4 was found to be significantly associated with recurrence. In a multivariate analysis, the weak expression of PRDX4—rather than other pathological features of high invasiveness—predicted a poor prognosis. In vitro, the viability of human PTC cells was significantly suppressed after PRXD4 plasmid transfection. Conclusion: The weak expression of PRDX4 can predict recurrence with a potential poor prognosis in advanced PTC.

  • Open Access

    Novel Platform for Regulation of Extracellular Vesicles and Metabolites Secretion from Cells Using a Multi-Linkable Horizontal Co-Culture Plate

    by Takeo Shimasaki, Satoko Yamamoto, Risa Omura, Kagenori Ito, Yumiko Nishide, Hideki Yamada, Kazumi Ohtomo, Tomo Ishisaka, Keiichiro Okano, Takenori Ogawa, et al.

    Microfluidics is applied in biotechnology research via the creation of microfluidic channels and reaction vessels. Filters are considered to be able to simulate microfluidics. A typical example is the cell culture insert, which comprises two vessels connected by a filter. Cell culture inserts have been used for years to study cell-to-cell communication. These systems generally have a bucket-in-bucket structure and are hereafter referred to as a vertical-type co-culture plate (VTCP). However, VTCPs have several disadvantages, such as the inability to simultaneously observe samples in both containers and the inability of cell-to-cell communication through the filters at high cell densities. In this study, we developed a novel horizontal-type co-culture plate (HTCP) to overcome these disadvantages and confirm its performance. In addition, we clarified the migration characteristics of substances secreted from cells in horizontal co-culture vessels. It is generally assumed that less material is exchanged between the horizontal vessels. However, the extracellular vesicle (EV) transfer was found to be twice as high when using HTCP. Other merits include control of the degree of co-culture via the placement of cells. We believe that this novel HTCP container will facilitate research on cell-to-cell communication in various fields.


  • Superior mediastinal lymphadenopathy by silicosis mimicking metastasis of papillary thyroid carcinoma – Case report and literature review

    by Toshiaki Tsukatani, Hideki Niwa, Takeshi Komori, Tatsuya Yoneyama, Hiroyuki Tsuji, Takatoshi Michigishi, Kunihiko Yokoyama, Tomokazu Yoshizaki


  • Open Access

    Third Epidemiological Analysis of Nasopharyngeal Carcinoma in the Central Region of Japan from 2006 to 2015

    by Masafumi Kanno, Norihiko Narita, Yasushi Fujimoto, Naohiro Wakisaka, Tomokazu Yoshizaki, Takeshi Kodaira, Chiyoko Makita, Yuichiro Sato, Keisuke Yamazaki, Takanori Wakaoka, et al.

    The present study aimed to clarify the incidence and clinical outcomes of nasopharyngeal carcinoma (NPC) in the Chubu region of Japan from 2006 to 2015, compared with previous reports. A retrospective analysis was conducted based on medical records from 40 hospitals located in the Chubu region in the central Japanese main island, with a population of around 22.66 million individuals. This study was designed in line with to two previous clinical studies into NPC conducted in the same area of Japan. We recruited NPC patients diagnosed in hospitals across this area over a 10-year period (2006–2015) using a questionnaire about sex, age, primary site, clinical symptoms, pathology, Union for International Cancer Control (UICC) staging, serological exam, treatment, and survival. A total of 620 NPC patients were identified. The age-standardized incidence of NPC from 2006 to 2015 was 0.27 per 100,000 individuals per year. There were no significant differences between this study and the previous two studies conducted in the same area of Japan. The five-year overall survival rate for all patients was 75.9%, while those for patients with stages I, II, III, and IVA were 97%, 91%, 79%, and 68%, respectively. The age-standardized annual incidence of NPC in the present study was 0.27 per 100,000 individuals per year, which was relatively low and stable. The five-year overall survival rate for all NPC patients was significantly improved in this decade compared with previous studies. The smoking rates in male and female NPC patients were 64.5% and 18.8%, respectively, thereby suggesting the involvement of smoking in the incidence of NPC.


  • A case of intestinal-type adenocarcinoma treated with skull base surgery after induction chemotherapy

    by Takuya Noda, Yukari Nakamura, Takaki Miwa, Yuzo Shimode, Hiroyuki Tsuji, Takuya Akai, Masanobu Yamashita

    症例は58歳男性。半年ほど前より右鼻閉と頻回の鼻出血を主訴に前医受診。右鼻腔内に出血を伴う壊死性腫瘍を認め,生検の結果adenocarcinomaの診断であった。造影CTでは右篩骨洞を中心に造影効果を有する腫瘤性病変を認め,前頭蓋底,右眼窩内側壁への浸潤が疑われた。またMRI検査ではT1強調像で造影効果を受ける低信号と高信号の混在する腫瘍を認めた。まずシスプラチン,フルオロウラシル,ロイコボリンを用いた導入化学療法を施行した後,脳神経外科と形成外科と合同で頭蓋底手術を施行した。術後病理学的所見ではBarnesの分類でpapillary-typeの診断であり腫瘍断端は陰性であった。術後照射として放射線外照射を計50Gy施行し,術後半年経過した現在無再発生存中である。


  • Pathological study on preoperative concurrent chemoradiation for advanced hypopharyngeal cancer

    by Toshiya Inoue, Motoki Nagata, Hisaya Yukawa, Manabu Ogura, Masao Yagi, Takuo Fujisawa, Makoto Miyamoto, Satoshi Chikano, Hirokazu Takemura, Toshio Yamashita, et al.


  • A Phase I Study of Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Carcinoma

    by Hiroyuki Tsuji, Takayoshi Kiba, Motoki Nagata, Toshiya Inoue, Hisaya Yukawa, Toshio Yamashita, Yuzo Shimode, Hideyuki Murata, Kenji Nagata, Koichi Tomoda

    Objective: Chemoradiation based on S-1, a novel oral antitumor agent of fluorinated pyrimidines, is the treatment for T2N0 glottic carcinoma; however, the optimal scheduling and dosing have still not been established. A phase I study was conducted to determine the maximum tolerated dose of S-1 with radiotherapy of 2 Gy/day for 5 days a week to a total dose of 60 Gy. Endpoints of this study were to examine the toxicity profile of this regimen and to determine the recommended dose of S-1. Methods: Concomitant administration with the above-mentioned radiotherapy of S-1 once a day for 2 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and 2 weeks on the drug with the dose escalating from S-1 60 mg/body (level 1) to 80 mg/body/day (level 2), and then to 100 mg/body/day (level 3). Results: Twenty-one patients were valid for safety. Eighteen patients were enrolled in the dose-escalation phase. In all patients, S-1 was administered. The maximum tolerated dose was determined to be 100 mg/body/day and the dose-limiting toxicity was indicated by the onset of grade 3 chemoradiation dermatitis. Therefore, the determined recommended dose of S-1 was 80 mg/body/day. Objective response according to Response Evaluation Criteria in Solid Tumors were observed in 20 of 21 patients who had measurable disease (95.2%). Conclusion: Concurrent S-1 and radiotherapy was feasible and well tolerated, and was suggested to produce a worthwhile response in T2N0 glottic carcinoma. These results warrant further investigation, and a phase II has already been started.


  • Clinical Study of Parapharyngeal Space Tumors

    by Hiroyuki Tsuji, Masao Yagi, Masayuki Minamino, Motoki Nagata, Hisaya Yukawa, Toyohiko Minami, Yuzo Shimode, Toshio Yamashita


  • Open Access

    Skull Base Surgery of Metastatic Renal Cell Carcinoma to the Ethmoid Sinus

    by Mariko Omae, Masayuki Minamino, Hiroyuki Tsuji, Motoki Nagata, Hisaya Yukawa, Katsuhiro Kawakami, Shigeo Kyuutoku, Toshio Yamashita

    • 1 September 2004
      • Vol. 32  (9) , 985-93

    [Clinico-pathology of skull tumor: aneurysmal bone cyst, fibrous dysplasia, eosinophilic granuloma].

    by Keiji Kawamoto, Masafumi Ohuchi, Shigeo Kyutoku, Hiroyuki Tsuji, Toshio Yamashita, Yasuaki Nakashima